Literature DB >> 31289142

Unilateral motor progression in MS: Association with a critical corticospinal tract lesion.

Elia Sechi1, B Mark Keegan2, Timothy J Kaufmann1, Orhun H Kantarci1, Brian G Weinshenker1, Eoin P Flanagan2.   

Abstract

OBJECTIVE: Progressive motor impairment anatomically attributable to a single critical demyelinating lesion on eloquent corticospinal tract locations occurs in progressive solitary sclerosis and in some patients with multiple sclerosis (MS) with highly restricted CNS lesion burden (2-5 lesions). We determined whether a similar critical lesion is found in patients with MS with unilateral motor progression and unlimited lesion burden.
METHODS: In this observational study, we retrospectively identified Mayo Clinic patients (January 1, 1996-December 31, 2017) with an MS diagnosis (2017 McDonald criteria), ≥1 year of exclusively unilateral motor progression, and >5 demyelinating lesions on MRI. A blinded neuroradiologist identified a single critical lesion (last available MRI) based on prominent size, atrophy, and eloquent corticospinal tract location (spinal cord lateral columns, medullary pyramids, cerebral peduncles, internal capsules). We then determined whether the motor impairment was anatomically attributable to the identified lesion.
RESULTS: Thirty-eight patients with MS were included: 20 (53%) with primary progressive MS and 18 (47%) with secondary progressive MS. Median age at progression onset was 54 (range 39-73) years. Median Expanded Disability Status Scale score was 5 (range 2.5-7.5) at the last follow-up (median 132.5 months from symptom onset, range 23-390 months). A single critical lesion was identified in 25 of 38 cases (66%): 19 in the cervical cord and 6 in the thoracic cord. In the remaining patients, >1 potential critical lesions were present. The overall probability to detect demyelinating lesions was higher along the corticospinal tract where the motor deficit localized (38 of 38 [100%]) than on the contralateral side (15 of 38 [39%]) (p < 0.0001).
CONCLUSIONS: In patients with MS with unilateral motor progression, the motor deficit may be attributable to a single critical corticospinal tract lesion.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Year:  2019        PMID: 31289142     DOI: 10.1212/WNL.0000000000007944

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.

Authors:  Anne Kerbrat; Charley Gros; Atef Badji; Elise Bannier; Francesca Galassi; Benoit Combès; Raphaël Chouteau; Pierre Labauge; Xavier Ayrignac; Clarisse Carra-Dalliere; Josefina Maranzano; Tobias Granberg; Russell Ouellette; Leszek Stawiarz; Jan Hillert; Jason Talbott; Yasuhiko Tachibana; Masaaki Hori; Kouhei Kamiya; Lydia Chougar; Jennifer Lefeuvre; Daniel S Reich; Govind Nair; Paola Valsasina; Maria A Rocca; Massimo Filippi; Renxin Chu; Rohit Bakshi; Virginie Callot; Jean Pelletier; Bertrand Audoin; Adil Maarouf; Nicolas Collongues; Jérôme De Seze; Gilles Edan; Julien Cohen-Adad
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

2.  Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Olayinka Oladosu; Wei-Qiao Liu; Lenora Brown; Bruce G Pike; Luanne M Metz; Yunyan Zhang
Journal:  Front Hum Neurosci       Date:  2022-08-12       Impact factor: 3.473

3.  Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions.

Authors:  Benan Barakat; Steve Messina; Shreya Nayak; Roman Kassa; Elia Sechi; Eoin P Flanagan; Orhun Kantarci; Brian G Weinshenker; B Mark Keegan
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-01-12

4.  Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.

Authors:  Elia Sechi; Karl N Krecke; Steven A Messina; Marina Buciuc; Sean J Pittock; John J Chen; Brian G Weinshenker; A Sebastian Lopez-Chiriboga; Claudia F Lucchinetti; Nicholas L Zalewski; Jan Mendelt Tillema; Amy Kunchok; Salvatore Monaco; Padraig P Morris; James P Fryer; Adam Nguyen; Tammy Greenwood; Stephanie B Syc-Mazurek; B Mark Keegan; Eoin P Flanagan
Journal:  Neurology       Date:  2021-07-14       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.